Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)
Open accessThe DOI matches its Crossref record; 384 of the 384 references it cites were found in a registry or an index.
Abstract
A panel of experts was convened by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) to update the 2010 clinical practice guideline on Clostridium difficile infection (CDI) in adults. The update, which has incorporated recommendations for children (following the adult recommendations for epidemiology, diagnosis, and treatment), includes significant changes in the management of this infection and reflects the evolving controversy over best methods for diagnosis. Clostridium difficile remains the most important cause of healthcare-associated diarrhea and has become the most commonly identified cause of healthcare-associated infection in adults in the United States. Moreover, C. difficile has established itself as an important community pathogen. Although the prevalence of the epidemic and virulent ribotype 027 strain has declined markedly along with overall CDI rates in parts of Europe, it remains one of the most commonly identified strains in the United States where it causes a sizable minority of CDIs, especially healthcare-associated CDIs. This guideline updates recommendations regarding epidemiology, diagnosis, treatment, infection prevention, and environmental management.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clostridium difficile is a Gram‐positive extracellular pathogen, which remains localized to the gastrointestinal tract but can cause severe toxin‐mediated gastrointestinal pathology, with a mortality rate of up to 6%. 67 , 68”
From The battle for iron in enteric infections (2020) · cites this paper as [68]
Citations
Cites
Multistate point-prevalence survey of health care-associated infections
Magill, S. S., Edwards, J. R., Bamberg, W., Beldavs, Z. G., Dumyati, G., Kainer, M. A., Lynfield, R., Maloney, M., McAllister-Hollod, L., Nadle, J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1306801 · Cited by 3,931
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
Stool form scale as a useful guide to intestinal transit time
Lewis, S. J., & Heaton, K. W. (1997) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529709011203 · Cited by 3,244
Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., & Wilcox, M. H. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,942
Self-citationBurden of Clostridium difficile Infection in the United States
Lessa, F. C., Mu, Y., Bamberg, W. M., Beldavs, Z. G., Dumyati, G. K., Dunn, J. R., Farley, M. M., Holzbauer, S. M., Meek, J. I., Phipps, E. C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1408913 · Cited by 2,641
Self-citationDethlefsen, L., Huse, S., Sogin, M. L., & Relman, D. A. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060280 · Cited by 2,361
An Epidemic, Toxin Gene–Variant Strain of Clostridium difficile
McDonald, L. C., Killgore, G. E., Thompson, A., Owens, R. C., Kazakova, S. V., Sambol, S. P., Johnson, S., & Gerding, D. N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051590 · Cited by 2,006
Self-citationLoo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M. D., Michaud, S., Bourgault, A.-M., Nguyen, T., Frenette, C., Kelly, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051639 · Cited by 1,946
Self-citationGoing from evidence to recommendations
Guyatt, G. H., Oxman, A. D., Kunz, R., Falck-Ytter, Y., Vist, G. E., Liberati, A., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39493.646875.ae · Cited by 1,810
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., Gorbach, S., Sears, P., & Shue, Y.-K. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910812 · Cited by 1,585
Research works printed but not linked: 3
- Health Protection Agency, 2005, Outbreak of Clostridium difficile infection in a hospital in southeast England, CDR Wkly, 15
- Tleyjeh, 2012, Association between acid-suppression therapy and Clostridium difficile infection: a systematic review and meta-analysis, Clin Microbiol Infect, 18, 113
- Polage, 2015, Overdiagnosis of Clostridium difficile infection in the molecular test era, JAMA Intern Med, 175, 1792, 10.1001/jamainternmed.2015.4114 · DOI · Paper page
Cited by
Items 501–600 of 1,000
Wu, X., Dai, M., Buch, H., Bai, J., Long, W.-W., Long, C., Tang, X., Tu, H., Zhang, R., Zhu, C., et al. (2019) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284819869144 · Cited by 25
Luo, Y., Cheong, E. Y. L., Bian, Q., Collins, D. A., Ye, J., Shin, J. H., Yam, W. C., Takata, T., Song, X., Wang, X., et al. (2019) · Emerging Microbes & Infections · doi:10.1080/22221751.2019.1682472 · Cited by 26
“CA-CDI were defined on the basis of the Society for Healthcare Epidemiology of America and the Infectious Diseases Society of America guidelines [3,20].”
MethodKumar, V., & Fischer, M. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1689952 · Cited by 27
“is severe, or for the treatment of fulminant CDI with no response to standard therapy after 48 h [17,18].”
BackgroundMy Treatment Approach to Clostridioides difficile Infection
Khanna, S. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.03.033 · Cited by 25
Kim, P., Gadani, A., Abdul‐Baki, H., Mitre, R., & Mitre, M. (2019) · JGH Open · doi:10.1002/jgh3.12093 · Cited by 24
Routes of dispersion of antibiotic resistance genes from the poultry farm system
Scicchitano, D., Babbi, G., Palladino, G., Turroni, S., Mekonnen, Y. T., Laczny, C. C., Wilmes, P., Leekitcharoenphon, P., Castagnetti, A., D’Amico, F., et al. (2023) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2023.169086 · Cited by 32
Origüen, J., Orellana, M. Á., Fernández‐Ruiz, M., Corbella, L., Juan, R. S., Ruiz‐Ruigómez, M., López‐Medrano, F., Lizasoaín, M., Ruiz‐Merlo, T., de la Calle, G. M., et al. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.01125-18 · Cited by 24
“The latest guidelines endorsed by the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA) recommended a multistep algorithm (1) as the most effective strategy for diagnosing CDI and minimizing overdiagnosis among colonized individuals.”
Peng, Z., Wang, S., Gide, M., Zhu, D., Patabendige, H. M. L. W., Li, C., Cai, J., & Sun, X. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.03234 · Cited by 24
Rubio‐Terres, C., Aguado, J. M., Almirante, B., Cobo, J., Grau, S., Salavert, M., Sánchez, E. G. A., Gutiérrez, C. L., & Rubio-Rodríguez, D. (2019) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-019-03503-4 · Cited by 27
“In this regard, several assumptions were made in the model, which are described in Online Resource 1 [10, 23].”
BackgroundMethodManagement of Clostridioides difficile colitis: insights for the gastroenterologist
Saha, S., & Khanna, S. (2019) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284819847651 · Cited by 27
Banking feces: a new frontier for public blood banks?
Baunwall, S. M. D., Hvas, C. L., Dahlerup, J. F., Mikkelsen, S., Ehlers, L. H., Hammeken, L. H., Licht, T. R., Bahl, M. I., & Erikstrup, C. (2019) · Transfusion · doi:10.1111/trf.15422 · Cited by 27
Global disparities in faecal microbiota transplantation research
Olesen, S. W., Panchal, P., Chen, J., Budree, S., & Osman, M. (2020) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(19)30452-2 · Cited by 25
Phanchana, M., Phetruen, T., Harnvoravongchai, P., Raksat, P., Ounjai, P., Chankhamhaengdecha, S., & Janvilisri, T. (2020) · Scientific Reports · doi:10.1038/s41598-020-63199-x · Cited by 24
Allegretti, J. R., Elliott, R. J., Ladha, A., Njenga, M., Warren, K., OʼBrien, K., Budree, S., Osman, M., Fischer, M., Kelly, C. R., et al. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1768777 · Cited by 25
Self-citationMutai, W. C., Mureithi, M., Anzala, O., Revathi, G., Kullin, B., Burugu, M., Kyanya, C. K., Odoyo, E., Otieno, P., & Musila, L. A. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.604986 · Cited by 28
Public-Health-Driven Microfluidic Technologies: From Separation to Detection
Zhang, X., Xu, X., Wang, J., Wang, C., Yan, Y., Wu, A., & Ren, Y. (2021) · Micromachines · doi:10.3390/mi12040391 · Cited by 26
Su, F., Luo, Y., Yu, J., Shi, J., Zhao, Y., Yan, M., Huang, H., & Tan, Y. (2021) · European journal of medical research · doi:10.1186/s40001-021-00508-8 · Cited by 24
Nerber, H. N., & Sorg, J. A. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009516 · Cited by 24
Tomkovich, S., Taylor, A., King, J., Colovas, J., Bishop, L., McBride, K., Royzenblat, S. K., Lesniak, N. A., Bergin, I. L., & Schloss, P. D. (2021) · mSphere · doi:10.1128/msphere.00629-21 · Cited by 24
“America and Society for Healthcare Epidemiology of America guidelines (55).”
BackgroundMonaghan, T. M., Duggal, N. A., Rosati, E., Griffin, R., Hughes, J., Roach, B., Yang, D. Y., Wang, C., Wong, K., Saxinger, L. M., et al. (2021) · Cells · doi:10.3390/cells10113234 · Cited by 23
Diagnostic Stewardship in Clinical Microbiology, Essential Partner to Antimicrobial Stewardship
Sullivan, K. V. (2021) · Clinical Chemistry · doi:10.1093/clinchem/hvab206 · Cited by 25
Collins, D. A., & Riley, T. V. (2022) · Letters in Applied Microbiology · doi:10.1111/lam.13664 · Cited by 30
Wang, S., Zhu, D., & Sun, X. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00263-22 · Cited by 25
Phage therapy for Clostridioides difficile infection
Fujimoto, K., & Uematsu, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1057892 · Cited by 32
Mengoli, M., Barone, M., Fabbrini, M., D’Amico, F., Brigidi, P., & Turroni, S. (2022) · Genes · doi:10.3390/genes13122200 · Cited by 25
Fecal Microbiota Transplantation in Patients Co-Infected with SARS-CoV2 and Clostridioides difficile
Boicean, A., Neamtu, B. M., Bîrsan, S., Batâr, F., Tanasescu, C. A. H., Dura, H., Roman, M. D., Hasegan, A. G., Bratu, D. G., Mihetiu, A. F., et al. (2022) · Biomedicines · doi:10.3390/biomedicines11010007 · Cited by 25
“Our results showed that in ore than 90% of the whole cohort (study and control groups), specific risk factors such as stroke, diabetes, obesity, and hypertension were present as important comorbidities for both infections, which is consistent with the current literature [11,12,16,17,19].”
BackgroundResultFidaxomicin to prevent recurrent Clostridioides difficile : what will it cost in the USA and Canada?
Patel, D., Senécal, J., Spellberg, B. J., Morris, A. M., Saxinger, L. M., Footer, B. W., McDonald, E. G., & Lee, T. C. (2022) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlac138 · Cited by 31
Malone, D. C., Armstrong, E. P., Gratie, D., Pham, S. V., & Amin, A. (2023) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2022.369 · Cited by 24
Moon, R. C., Bleak, T. C., Rosenthal, N. A., Couturier, B. A., Hemmert, R. B., Timbrook, T. T., Brown, H., & Fang, F. C. (2023) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002186 · Cited by 27
Hromada, S. E., & Venturelli, O. S. (2023) · PLoS Biology · doi:10.1371/journal.pbio.3002100 · Cited by 26
“line treatment, is now only recommended in rare cases due to an observed decrease in its clinical effectiveness [23,24].”
BackgroundMadden, G. R., Poulter, M. D., & Sifri, C. D. (2018) · Diagnosis · doi:10.1515/dx-2018-0012 · Cited by 24
“The 2017 IDSA-SHEA guidelines suggest that institutions using an NAAT alone approach without preagreed institutional criteria should adopt a multistep testing algorithm in order to improve test performance (positive and negative predictive value) or else implement preagreed institutional criteria for testing [7].”
InfluentialOutcomes of Community and Healthcare-onsetClostridium difficileInfections
Mora-Pinzon, M. C., Buie, R. W., Liou, J., Shirley, D. K., Evans, C. T., Ramanathan, S., Poggensee, L., & Safdar, N. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy715 · Cited by 33
Clinical review of Clostridium difficile infection: an update on treatment and prevention
Daniels, L. M., & Kufel, W. D. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1524872 · Cited by 32
Howard-Anderson, J. R., Sexton, M. E., Robichaux, C. J., Wiley, Z., Varkey, J. B., Suchindran, S., Albrecht, B., Jones, K. A., Fridkin, S. K., & Jacob, J. T. (2020) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2020.12 · Cited by 25
Clostridium difficile in inflammatory bowel disease
Alhobayb, T. Y., & Ciorba, M. A. (2023) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000949 · Cited by 27
“As a result of numerous randomized trials comparing FMT to standard antibiotic treatment and placebo [44,45], FMT is now a recommended therapy for recurrent CDI according to treatment guidelines [19].”
BackgroundBerry, P., & Khanna, S. (2023) · BioDrugs · doi:10.1007/s40259-023-00617-2 · Cited by 23
Juul, F. E., Bretthauer, M., Johnsen, P. H., Samy, F., Tonby, K., Berdal, J., Hoff, D. A. L., Ofstad, E. H., Abraham, A., Seip, B., et al. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-03285 · Cited by 30
Antibiotic Use and the Risk of Hospital-Onset Clostridioides Difficile Infection
Gilboa, M., Regev‐Yochay, G., Meltzer, E., Cohen, I., Peretz, Y., Zilberman‐Daniels, T., Segev, A., Amit, S., Yahav, D., & Barda, N. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.25252 · Cited by 27
Poirier, D., Gervais, P., Fuchs, M., Roussy, J.-F., Paquet-Bolduc, B., Trottier, S., Longtin, J., Loo, V. G., & Longtin, Y. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz626 · Cited by 23
Self-citationEvaluation of Six Weekly Oral Fecal Microbiota Transplants in People with HIV
Utay, N. S., Monczor, A. N., Somasunderam, A., Lupo, S., Jiang, Z., Alexander, A. S., Finkelman, M., Vigil, K. J., Lake, J. E., Hanson, B., et al. (2020) · Pathogens and Immunity · doi:10.20411/pai.v5i1.388 · Cited by 25
Ooijevaar, R. E., van Nood, E., Goorhuis, A., Terveer, E. M., van Prehn, J., Verspaget, H. W., van Beurden, Y. H., Dijkgraaf, M. G. W., & Keller, J. J. (2021) · Microorganisms · doi:10.3390/microorganisms9030548 · Cited by 24
Nanobiosystems for Antimicrobial Drug-Resistant Infections
Gkartziou, F., Giormezis, N., Spiliopoulou, I. T., & Antimisiaris, S. G. (2021) · Nanomaterials · doi:10.3390/nano11051075 · Cited by 27
“difficile, not affecting the physiological intestinal flora [121].”
BackgroundFeuerstadt, P., Aroniadis, O. C., Svedlund, F. L., Garcia, M. B., Stong, L., Boules, M., & Khanna, S. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-021-07141-9 · Cited by 23
Wu, X., Ai, R., Xu, J., Wen, Q., Pan, H. Q., Zhang, Z. H., Wang, N., Fang, Y., Ding, D. F., Wang, Q., et al. (2023) · Journal of Digestive Diseases · doi:10.1111/1751-2980.13227 · Cited by 23
Antibacterial activity of rhodomyrtone on Clostridium difficile vegetative cells and spores in vitro
Srisuwan, S., Mackin, K. E., Hocking, D. M., Lyras, D., Bennett-Wood, V. R., Voravuthikunchai, S. P., & Robins-Browne, R. M. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.08.014 · Cited by 23
Risk factors for community-associated Clostridioides difficile infection in young children
Weng, M. K., Adkins, S. H., Bamberg, W., Farley, M. M., Espinosa, C. C., Wilson, L. E., Perlmutter, R., Holzbauer, S., Whitten, T., Phipps, E. C., et al. (2019) · Epidemiology and Infection · doi:10.1017/s0950268819000372 · Cited by 23
“difficile, most frequently through faecal–oral transmission, can lead to asymptomatic colonisation or a range of clinical manifestations from mild diarrhoea to pseudomembranous colitis, bowel perforation or death [2, 3].”
BackgroundSelf-citationKim, K. O., Schwartz, M. A., Lin, O. S. T., Chiorean, M. V., & Glück, M. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00974-x · Cited by 27
“Probiotics appear to have some benefit in decreasing rCDI incidence, but they are not advocated for treatment of rCDI as much as prevention [10, 24].”
BackgroundWhite, N. C., Mendo-López, R., Papamichael, K., Cuddemi, C., Barrett, C. G., Daugherty, K., Pollock, N. R., Kelly, C. P., & Alonso, C. D. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz978 · Cited by 23
Self-citationCharacterization of an Endolysin Targeting Clostridioides difficile That Affects Spore Outgrowth
Mondal, S. I., Akter, A., Draper, L. A., Ross, R. P., & Hill, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115690 · Cited by 24
“difficile is typically mediated by two major exotoxins, TcdA and TcdB, that cause intestinal epithelial damage and diarrhoea [8].”
BackgroundAncona, G., Alagna, L., Lombardi, A., Palomba, E., Castelli, V., Renisi, G., Dondossola, D. E., Iavarone, M. A., Muscatello, A., Gori, A., et al. (2021) · Infection and Immunity · doi:10.1128/iai.00376-21 · Cited by 23
Birch, T., Golan, Y., Rizzardini, G., Jensen, E. H., Gabryelski, L. J., Güriş, D., & Dorr, M. B. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky182 · Cited by 23
Alukal, J. J., Dutta, S., Surapaneni, B. K., Le, M., Tabbaa, O. M., Phillips, L. E., & Mattar, M. C. (2019) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12750 · Cited by 25
“is further supported by the 2018 Infectious Diseases Society of America guidelines.(4) Severe and complicated CDI presents with or develops at least one of the following signs or symptoms: admission to the ICU, hypotension with or without requiring the use of vasopressors, fever (≥38.”
MethodMancinetti, F., Marinelli, A., Boccardi, V., & Mecocci, P. (2024) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2024.111998 · Cited by 33
Clostridioides difficile pathogenesis and control
Chilton, C. H., Viprey, V. F., Normington, C., Moura, I. B., Buckley, A. M., Freeman, J., Davies, K., & Wilcox, M. H. (2025) · Nature Reviews Microbiology · doi:10.1038/s41579-025-01242-2 · Cited by 36
“Current guidance does not support testing of children aged ≤2 years old 3,15,55 .”
Self-citationSharma, S. K., Yip, C., Esposito, E. X., Sharma, P. V., Simon, M. P., Abel‐Santos, E., & Firestine, S. M. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00632 · Cited by 22
Gastrointestinal and Hepatobiliary Disease in Cystic Fibrosis
Gabel, M. E., Galante, G., & Freedman, S. D. (2019) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-1697591 · Cited by 24
Microbiome Anomalies in Allogeneic Hematopoietic Cell Transplantation
Schwabkey, Z. I., & Jenq, R. R. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-052918-122440 · Cited by 23
Hung, Y., Tsai, C.-S., Tsai, B., Tsai, P.-J., Lee, Y.-T., Lee, J., Liu, H.-C., Hsueh, P., Lee, C., & Ko, W. (2021) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2021.02.002 · Cited by 24
Jiang, Y., Sarpong, E., Sears, P. S., & Obi, E. N. (2021) · Infectious Diseases and Therapy · doi:10.1007/s40121-021-00480-0 · Cited by 22
Wombwell, E., Bransteitter, B. A., & Gillen, L. R. (2021) · Mycoses · doi:10.1111/myc.13375 · Cited by 24
Vecchio, L. E. D., Fiorani, M., Tohumcu, E., Bibbò, S., Porcari, S., Mele, M. C., Pizzoferrato, M., Gasbarrini, A., Cammarota, G., & Ianiro, G. (2022) · Microorganisms · doi:10.3390/microorganisms10071315 · Cited by 26
“The presence of systemic signs, such as hypotension, shock, ileus, or megacolon, defines a fulminant CDI [1,66,67].”
BackgroundMethodInfluentialSexually Transmitted Infections in Older Adults
Epps, P. V., Musoke, L., & McNeil, C. J. (2023) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2022.11.003 · Cited by 25
Sharma, A. K., Krzeminski, J., Weissig, V., Hegarty, J. P., & Stewart, D. B. (2018) · The Journal of Antibiotics · doi:10.1038/s41429-018-0056-9 · Cited by 22
Thanissery, R., Zeng, D., Doyle, R. G., & Theriot, C. M. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01206 · Cited by 20
An Engineered Synthetic Biologic Protects Against Clostridium difficile Infection
Vedantam, G., Kochanowsky, J. A., Lindsey, J., Mallozzi, M., Roxas, J. L., Adamson, C. C., Anwar, F., Clark, A. E., Claus-Walker, R. A., Mansoor, A., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02080 · Cited by 25
Prolonged oral vancomycin for secondary prophylaxis of relapsing Clostridium difficile infection
Zhang, K., Beckett, P., Abouanaser, S., Stankus, V., Lee, C., & Smieja, M. (2019) · BMC Infectious Diseases · doi:10.1186/s12879-019-3676-1 · Cited by 23
Kimura, T., Snijder, R. J., & Sugitani, T. (2019) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2019.03.011 · Cited by 23
Clostridioides difficile Infection in the Stem Cell Transplant and Hematologic Malignancy Population
Misch, E. A., & Safdar, N. (2019) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2019.02.010 · Cited by 25
Current and future trends in clostridioides (clostridium) difficile infection management
Khanna, S., & Gerding, D. N. (2019) · Anaerobe · doi:10.1016/j.anaerobe.2019.04.010 · Cited by 27
Self-citationRapid Detection of Clostridium difficile Toxins in Stool by Raman Spectroscopy
Koya, S. K., Yurgelevic, S. M., Brusatori, M., Huang, C., Diebel, L. N., & Auner, G. W. (2019) · Journal of Surgical Research · doi:10.1016/j.jss.2019.06.039 · Cited by 22
Non-antibiotic therapy forClostridioides difficileinfection: a review
Yang, J., & Yang, H. (2019) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2019.1648377 · Cited by 29
“difficile carriers without symptoms [28].”
BackgroundInfluentialGastrointestinal tract microbiota modifications in systemic sclerosis
Volkmann, E. R., & Hoffmann‐Vold, A. (2020) · European Journal of Rheumatology · doi:10.5152/eurjrheum.2019.19103 · Cited by 23
Dubberke, E. R., Gerding, D. N., Kelly, C. P., Garey, K. W., Rahav, G., Mosley, A., Tipping, R., & Dorr, M. B. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa157 · Cited by 22
“These findings have resulted in significant revisions to treatment guidelines, and in the 2017 Infectious Diseases Society of America/Society of Healthcare Epidemiology of America (IDSA/SHEA) CDI guidelines, the recommended first-line antibacterial drug treatment for severe and nonsevere CDI was vancomycin or fidaxomi…”
BackgroundMethodResultInfluentialSelf-citationZou, J., Leung, V. C. M., Champagne, S., Hinch, M., Wong, A., Lloyd‐Smith, E., Nguyen, T. T., Romney, M. G., Sharma, A., Payne, M., et al. (2018) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-018-3383-7 · Cited by 22
“Patients with an indeterminate result were reviewed by either the antimicrobial stewardship (ASP) physician or pharmacist to assess whether the patient was colonized or infected, based on new-onset ≥ 3 loose stools in 24 h without an alternate diagnosis [3, 7].”
MethodReveles, K. R., Yang, M., García-Horton, V., Edwards, M. L., Guo, A. X., Lodise, T. P., Bochan, M. R., Tillotson, G., & Dubberke, E. R. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02498-x · Cited by 25
“In the 2017 Clinical Practice Guideline Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA), vancomycin or fidaxomicin were recommended for initial CDI episodes, whereas in their 2021 update, fidaxomicin is the preferred first-line antibiotic over vanco…”
BackgroundSelf-citationPalaiopanos, K., Krystallaki, D., Μellou, K., Kotoulas, P., Kavakioti, C.-A., Vorre, S., Vertsioti, G., Gkova, M., Maragkos, A., Tryfinopoulou, K., et al. (2024) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-024-01367-8 · Cited by 21
Fecal Microbiota Transplantation: A Prospective Treatment for Type 2 Diabetes Mellitus
Zhou, X., Chen, R., Cai, Y., & Chen, Q. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s447784 · Cited by 25
Predicting Clostridioides difficile infection outcomes with explainable machine learning
Madden, G. R., Boone, R., Lee, E., Sifri, C. D., & Petri, W. A. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105244 · Cited by 24
New Host-Directed Therapeutics for the Treatment of Clostridioides difficile Infection
Andersson, J. A., Peniche, A. G., Galindo, C. L., Boonma, P., Sha, J., Luna, R. A., Savidge, T., Chopra, A. K., & Dann, S. M. (2020) · mBio · doi:10.1128/mbio.00053-20 · Cited by 23
Hammeken, L. H., Baunwall, S. M. D., Hvas, C. L., & Ehlers, L. H. (2021) · Health Economics Review · doi:10.1186/s13561-021-00301-7 · Cited by 21
Luminal Gastrointestinal Manifestations of Cystic Fibrosis
Burton, S. J., Hachem, C., & Abraham, J. M. (2021) · Current Gastroenterology Reports · doi:10.1007/s11894-021-00806-5 · Cited by 24
Esposito, G., Corpetti, C., Pesce, M., Seguella, L., Annunziata, G., Re, A., Vincenzi, M., Lattanzi, R., Lu, J., Sanseverino, W., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.639728 · Cited by 23
Hourigan, S. K., Nicholson, M. R., Kahn, S. A., & Kellermayer, R. (2021) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000003229 · Cited by 21
Oral Vancomycin as Secondary Prophylaxis for Clostridioides difficile Infection
Bao, H., Lighter, J., Dubrovskaya, Y., Merchan, C., Siegfried, J., Papadopoulos, J., & Jen, S.-P. P. (2021) · PEDIATRICS · doi:10.1542/peds.2020-031807 · Cited by 22
Risk Factors for Recurrence of Clostridioides difficile in Hospitalized Patients
Alrahmany, D., Ereshefsky, B. J., Nekidy, W. S. E., Harb, G., Pontiggia, L., & Ghazi, I. M. (2021) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2021.09.016 · Cited by 22
Brauer, M., Herrmann, J. E., Zühlke, D., Müller, R., Riedel, K., & Sievers, S. (2022) · Gut Pathogens · doi:10.1186/s13099-021-00475-9 · Cited by 21
“Moreover, the macrocyclic antibiotic Fidaxomicin is considered as the current gold standard in CDI therapy [3, 11].”
BackgroundAlonso, C. D., Marón, G. M., Kamboj, M., Carpenter, P. A., Gurunathan, A., Mullane, K. M., & Dubberke, E. R. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.02.013 · Cited by 22
Self-citationBrestrich, G., Angulo, F. J., Berger, F. K., Brösamle, C., Hagel, S., Leischker, A. H., Lübbert, C., Maechler, F., Merbecks, S.-S., Minarovic, N., et al. (2023) · Infectious Diseases and Therapy · doi:10.1007/s40121-023-00785-2 · Cited by 21
“Another reason could be the update of the CDI clinical treatment guideline in 2017 [4].”
BackgroundTrends in the epidemiology of Clostridioides difficile infection in Germany
Vehreschild, M. J. G. T., Schreiber, S., von Müller, L., Epple, H., Weinke, T., Manthey, C. F., Oh, J. S., Wahler, S., & Stallmach, A. (2023) · Infection · doi:10.1007/s15010-023-02044-5 · Cited by 25
Deane, A. M., Alhazzani, W. A., Guyatt, G. H., Finfer, S. R., Marshall, J. C., Myburgh, J., Zytaruk, N. L., Hardie, M. J., Saunders, L., Knowles, S., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-075588 · Cited by 22
“…C. difficile infection is defined as clinical features (diarrhoea (>3 episodes of unformed stools 36 or Bristol type 6 or 7 37 ) ileus, or toxic megacolon) and either microbiological evidence of toxin-producing C. difficile or pseudomembranous colitis on colonoscopy 38 in hospital within 90 days.”
Fecal Microbiota Transplantation: Indications, Methods, and Challenges
Lee, J. Y., Kim, Y., Kim, J., & Kim, J. K. (2024) · The Journal of Microbiology · doi:10.1007/s12275-024-00184-3 · Cited by 26
Gite, S., Archambault, D., Cappillino, M. P., Cunha, D., Dorich, V., Shatova, T. A., Tempesta, A., Walsh, B., Walsh, J. A., Williams, A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-26353-0 · Cited by 21
Heitman, T., DAY, A. J., & Bassani, A. S. (2019) · Children · doi:10.3390/children6050066 · Cited by 24
Nieto, M., Robles, J. C., Causse, M., Gutiérrez, L., Perez, M. C., Ferrer, R., Xercavins, M., Herrero, E., Sirvent, E., Fernández, C., et al. (2019) · Infectious Diseases and Therapy · doi:10.1007/s40121-019-0248-z · Cited by 24
“Empirical antifungal treatment in high-risk patients is currently recommended by the European Society for Clinical Microbiology and Infectious Diseases [28] as well as by the Infectious Diseases Society of America [29].”
BackgroundBabacan, N., & Tanvetyanon, T. (2019) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000270 · Cited by 21
Fecal microbiota transplantation in children: current concepts
Gurram, B., & Sue, P. K. (2019) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000787 · Cited by 23
Keller, J. J., Vehreschild, M. J. G. T., Hvas, C. L., Baunwall, S. M. D., Kupciskas, J., Link, A., Mulder, C. J. J., Goldenberg, S. D., Arasaradnam, R. P., Sokol, H., et al. (2019) · United European Gastroenterology Journal · doi:10.1177/2050640619887579 · Cited by 23
Baron, S. W., Ostrowsky, B. E., Nori, P., Drory, D. Y., Levi, M. H., Szymczak, W. A., Rinke, M. L., & Southern, W. N. (2019) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2019.309 · Cited by 21
“difficile Quik Chek Complete (Abbott, Chicago, IL) to test for glutamate dehydrogenase (GDH) and toxins A and B and (2) XPert C.”
BackgroundInfluentialGarza‐González, E., Mendoza-Olazarán, S., Morfín‐Otero, R., Ramírez-Fontes, A., Rodríguez‐Zulueta, P., Flores-Treviño, S., Bocanegra‐Ibarias, P., Maldonado-Garza, H. J., & Camacho-Ortíz, A. (2019) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2019/4549298 · Cited by 23
Virulence Factors of Clostridioides (Clostridium) difficile Linked to Recurrent Infections
Tijerina-Rodríguez, L., Villarreal-Treviño, L., Morfín‐Otero, R., Camacho-Ortíz, A., & Garza‐González, E. (2019) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2019/7127850 · Cited by 21
Metadata
- Authors
- McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., Loo, V., Shaklee Sammons, J., Sandora, T. J., & Wilcox, M. H.
- Affiliations
- Centers for Disease Control and Prevention (US)
- Edward Hines, Jr. VA Hospital (US)
- Loyola University Medical Center (US)
- St. Luke's Hospital (US)
- Johns Hopkins University (US)
- Children's Hospital of Philadelphia (US)
- Washington University in St. Louis (US)
- University of Houston (US)
- Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
- McGill University Health Centre (CA)
- Children’s Hospital of Philadelphia, Pennsylvania
- Boston Children's Hospital (US)
- Leeds Teaching Hospitals NHS Trust (GB)
- Corresponding author
- McDonald, L Clifford
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-02-15
- Volume
- 66
- Issue
- 7
- Pages
- e1-e48
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC6018983
- OpenAlex
- W2791326569
- Cited by
- 2,690
- References
- 383
- Citations by year
- 2026: 148 · 2025: 179 · 2024: 215 · 2023: 305 · 2022: 331 · 2021: 423 · 2020: 486 · 2019: 408 · 2018: 185
- FWCI
- 228.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion)
- Funders
- Agency for Health Research and Quality
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Health Sciences › Medicine › Infectious Diseases › Infection Control in Healthcare
- Health Sciences › Medicine › Microbiology (medical) › Bacterial Identification and Susceptibility Testing
- Keywords
- Clostridium difficile infection, nosocomial infections, healthcare-associated diarrhea, pediatric infection, diagnosis, treatment, infection control, environmental management, ribotype 027, community-acquired infections, epidemiology
- MeSH terms
- Adult, Child, Clostridium Infections, Diarrhea, Humans, Retrospective Studies, Societies, Societies, Medical, Clostridioides difficile, Infectious Disease Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.